Articles tagged with Multiple Sclerosis
A Phase II clinical trial found that an oral drug called ONO-4641 reduced the number of lesions in people with relapsing-remitting multiple sclerosis. The study showed significant decreases in Gd-enhancing brain lesions, with doses of 0.05mg, 0.10mg, and 0.15mg resulting in 82%, 92%, and 77% fewer lesions compared to placebo.
The Kessler Foundation has been awarded a $383,000 five-year grant from the National Multiple Sclerosis Society to fund postdoctoral fellowships in MS rehabilitation research. The program provides advanced training for scientists working towards careers dedicated to improving the lives of people with MS.
A study presented at the Society of Interventional Radiology's annual meeting found that angioplasty can provide symptom relief for MS patients with venous obstructions. The procedure showed significant safety findings and provided symptomatic benefit in 55% of individuals treated.
A minimally invasive endovascular treatment for CCSVI shows promise in improving physical- and mental health-related quality of life in individuals with multiple sclerosis. The study found significant short-term improvements in over 75% of those with relapsing remitting and primary progressive forms of MS.
Patients with relapsing onset MS who consumed alcohol, wine, coffee and fish took four to seven years longer to reach a walking aid than those who did not consume these items. In contrast, patients with progressive onset MS showed no significant differences in disease progression rates based on lifestyle factors.
A Kessler Foundation study found that people with multiple sclerosis perform poorly in memory and processing speed tests on hotter days. The research suggests a link between outdoor temperature and cognitive performance, which could impact clinical trials and treatment decisions.
Research found that women who had two or more pregnancies had a significantly reduced risk of developing MS symptoms, while men showed no association between children and MS risk. This study suggests a possible link between delayed motherhood and increased MS cases in women.
Helen Genova, a researcher at Kessler Foundation, has received the Women of Excellence Award in Health Sciences for her groundbreaking studies on cognitive fatigue in individuals with multiple sclerosis. Her innovative approach using functional MRI aims to develop more effective strategies for maintaining cognition and quality of life.
Academics at the University of Nottingham are recruiting patients with relapsing remitting multiple sclerosis to test the effect of a low dose of the helminth parasite Necator americanus on their immune system. The study aims to prove that hookworms can reduce MS symptoms and prevent relapses.
Researchers refuted the neurodegenerative hypothesis, which suggested myelin damage occurred without an immune system attack. The study found that immune defense played a role in triggering MS-like autoimmune disease.
A study published in Radiology found that computer-assisted cognitive rehabilitation improved attention and information processing skills in patients with relapsing-remitting multiple sclerosis. The rehabilitation program showed modifications in brain activity correlated with cognitive improvement, without structural changes in the brain.
Dr. Richard Ransohoff receives the 2012 John Dystel Prize for his groundbreaking work on understanding and treating multiple sclerosis. His research has led to a deeper understanding of MS progression and the development of novel therapeutic targets.
Scientists at the University of Nottingham discovered a new mechanism that explains how infections can trigger multiple sclerosis relapses. Regulatory T cells, which regulate immune responses, become less inhibitory when stimulated by bacterial or viral molecules, leading to increased inflammation.
Researchers have created a high-resolution virtual image of S1P1 receptors, critical in controlling MS and other diseases. The molecular map points toward promising new drug discovery paths.
A Wayne State University researcher is developing a model to focus on the causes of everyday MS symptoms. The goal is to provide more effective treatments and improve daily functioning for patients.
Researchers at Caltech have developed a gene therapy that stimulates the production of new oligodendrocytes from stem cells, enabling the brain to replace damaged myelin sheaths in demyelinating diseases like MS. The therapy uses leukemia inhibitory factor (LIF) to promote remyelination and reduce inflammation.
A recent study published in Neurology found that men are at higher risk of experiencing mild cognitive impairment (MCI) than women. The study, which analyzed data from 1,450 participants aged 70-89, revealed that the number of new cases of MCI per year was higher in men, affecting 72 per 1,000 people.
A new study by Kessler Foundation found that memory retraining using the modified Story Memory Technique (mSMT) increases cerebral activation in patients with multiple sclerosis. This suggests that behavioral interventions can positively affect brain function in MS, validating the clinical utility of cognitive rehabilitation.
A study published in Cell Stem Cell highlights the possibility of reversing ageing in the central nervous system for multiple sclerosis (MS) patients. The age-associated decline of remyelination, a regenerative process, can be reversed using inflammatory cells from young mice.
A study published in Cell Stem Cell found that defects in myelin sheath regeneration surrounding nerves can be at least partially corrected following exposure to young immune cells. This suggests that regenerative therapies may work throughout the duration of MS, regardless of age. The findings provide new hope for treating this disease.
Researchers have discovered a new mouse model for Multiple Sclerosis, using diabetic mice to replicate the disease's relapsing and remitting symptoms. This breakthrough may lead to the development of more effective treatments that turn temporary recovery into permanent repair.
A recent study published in Neurology reveals a sophisticated link between the Epstein-Barr virus (EBV) and multiple sclerosis (MS), potentially leading to new treatments and prevention strategies. Researchers found that EBV triggers inflammation and nerve cell damage in the brain, which is known to cause MS symptoms.
Multiple sclerosis may not be an autoimmune disease, but rather a metabolic disorder. This new framework could help guide researchers toward new treatments and ultimately a cure for the disease. The lipid hypothesis proposes that MS is caused by disruption of lipid homeostasis in the central nervous system.
Researchers at UTHealth found evidence that multiple sclerosis affects the thalamus, a brain region controlling cognitive function, sensory processing, and motor skills. The study used MRI scans to compare patients with MS to healthy controls, revealing volume loss in the thalamus related to disease severity.
Researchers at the University of Alberta have discovered a new way to track the progression of multiple sclerosis by using powerful MRI to measure iron levels in brain tissue. The study found that high iron levels are associated with physical disabilities and may be an early marker of MS.
A new collaborative study from the Mayo Clinic and Cleveland Clinic suggests that multiple sclerosis may progress from the outermost layers of the brain to its deep parts. The researchers found that the cortex is involved early in MS and may even be the initial target of disease.
A new study published in the New England Journal of Medicine found that multiple sclerosis begins in the cerebral cortex, contrary to previous theories. The research involved analyzing 563 brain biopsies and revealed distinct differences in lesions, providing clues for better disease management.
A study published in the American Journal of Pathology suggests laquinimod targets immune cells to increase neuroprotection in multiple sclerosis patients. The treatment increases brain-derived neurotrophic factor (BDNF) levels, contributing to neuron repair and limiting brain damage.
Neuromyelitis optica (NMO) is an inflammatory autoimmune disease that damages optic nerves and spinal cord. Mayo Clinic researchers have identified critical steps leading to myelin destruction, which could lead to better diagnosis and treatment of the disease.
A University at Buffalo study of 252 volunteers identified an association between chronic cerebrospinal venous insufficiency (CCSVI) and multiple sclerosis (MS) risk factors, including infectious mononucleosis, irritable bowel syndrome, and smoking. The findings suggest that CCSVI may be a vascular condition similar to MS, warranting f...
A modified Story Memory Technique was found to be effective in improving learning and memory deficits in people with multiple sclerosis. The treatment group showed greater activation in a widespread cortical network, indicating improved cognitive function.
Two Kessler Foundation researchers received over $100,000 in National Multiple Sclerosis Society grants to investigate cognitive impairments in MS. The studies aim to improve processing speed and understand the relationship between white matter damage and cognitive decline.
Researchers have discovered that connexin 36 protects mouse pancreatic beta-cells against immune molecules prevalent in type 1 diabetes. Additionally, a study found that PTHrP drives breast tumor initiation, progression, and metastasis in mice, suggesting it as a potential therapy target.
Researchers discovered that crocin in saffron exerts protective effects on brain cells and prevented damage in models of MS. The study also found a link between an ancient virus and cell stress leading to inflammation in the disease.
The study found that Ocrelizumab led to a 89% reduction in brain lesions and reduced the number of new multiple sclerosis attacks over 24 weeks. This suggests targeting B cells could help treat MS.
Research suggests that natural intestinal flora may play a crucial role in the emergence of multiple sclerosis. Beneficial bacteria can activate immune cells and trigger an overreaction of the immune system in genetically predisposed individuals. This finding has important implications for disease prevention and treatment.
Scientists have developed a sensor array that can diagnose multiple sclerosis from exhaled breath, offering a fast, inexpensive and non-invasive alternative to traditional methods. The technology has been tested in humans and shows promising results, rivaling the accuracy of spinal taps without pain or risk.
A potential new drug target has been discovered to stop debilitating effects of MS by preventing brain cell death caused by granzyme B. The target is the M6PR receptor, which allows granzyme B to enter neurons and wreak havoc.
A six-month randomized controlled trial found no added benefit from high-dose vitamin D over and above ongoing low-dose vitamin D supplementation in treating relapsing-remitting multiple sclerosis. The study involved 23 participants with MS, who received either high-dose or placebo high-dose vitamin D, and showed no significant differe...
Research suggests that shift work in teenagers may increase the risk of developing multiple sclerosis, a central nervous system autoimmune inflammatory disorder. Disruption of the circadian rhythm and sleep patterns are believed to contribute to this increased risk.
A team from the University of Utah has received a $275,000 NIH grant to study brain tissue from patients with primary progressive multiple sclerosis (PPMS) using advanced technology called deep sequencing. The goal is to identify viruses that might play a role in the development of PPMS and potentially lead to new treatments.
A new oral drug, teriflunomide, has been shown to significantly reduce the relapse rate of people with multiple sclerosis and slow the progression of the disease. The drug was found to be effective in increasing the time between relapses and reducing disease progression by almost 30%.
A systematic review found that taking natalizumab for two years lowers the number of MS patients who experience relapses and progression of disability. The medication also delays disease progression, according to MRI brain scans.
A meta-analysis found a strong association between CCSVI and multiple sclerosis, but the low quality of included studies prevents a definitive conclusion. The variation in study results suggests that factors such as sample size, ultrasound techniques, and training of operators may contribute to the heterogeneity.
A review of eight studies found an association between chronic cerebrospinal venous insufficiency and multiple sclerosis, but poor study quality and inconsistencies hinder definitive conclusions. Further research is needed to clarify the relationship.
A glucosamine-like dietary supplement, N-acetylglucosamine (GlcNAc), suppresses multiple sclerosis attacks by inhibiting abnormal T-cell growth and function. The study, published in The Journal of Biological Chemistry, suggests a novel mechanism for affecting T-cell function and autoimmunity.
Researchers at University of California - San Diego have discovered that inhibiting a single enzyme helps slow disease progression in a mouse model of multiple sclerosis. The study suggests that targeting fatty acid metabolism could lead to new therapies with fewer side effects.
Researchers at Cleveland institutions collaborate on a ground-breaking study testing the feasibility and safety of using mesenchymal stem cells to treat multiple sclerosis. The Phase 1 trial aims to decrease disease activity and promote repair in patients with MS.
Researchers identified 29 new genetic variants linked to multiple sclerosis, shedding light on immunological pathways and immune system involvement. The study confirms 23 known genetic associations and provides insight into a possible link between genetic and environmental risk factors.
An international team of scientists identified 29 new genetic variants linked to multiple sclerosis, providing key insights into the biology of the disease. The study confirms 23 previously known genetic associations and doubles the number of genes associated with MS.
A large international study has identified 29 new genetic variants associated with multiple sclerosis, providing key insights into the biology of the disease. The research highlights the pivotal role of the immune system in causing damage and helps explain the nature of the immune attack on the brain and spinal cord.
A recent study by Yale University researchers has identified more than two dozen new genetic variants linked to disease risk in multiple sclerosis and other autoimmune diseases. The findings suggest a common genetic basis for many devastating immune system disorders.
A new study examines the cost-effectiveness of MS drugs in the US, finding that they come at a high cost compared to basic therapy and other chronic diseases. The research suggests that reducing medication prices by 67% could improve the cost-benefit ratio and support earlier disease-modifying therapy.
A study analyzed data from 844 individuals with early-stage Multiple Sclerosis and found that disease-modifying drugs provide modest health gains, but their cost is more than 8 times higher than considered reasonable. The study's authors highlight the need to reevaluate treatment costs to control healthcare expenses.
People with multiple sclerosis are at risk of poor bone health in the early stages of the disease, with 51% experiencing osteoporosis or osteopenia. Low vitamin D levels can lead to reduced calcium absorption and bone mineralization.
New research from the American Academy of Neurology found that breastfeeding does not have a protective effect on multiple sclerosis relapses. In fact, women with high disease activity and high risk of postpartum relapses may need to resume MS treatment after giving birth.
A team of researchers has discovered a naturally occurring disease in monkeys that shares similarities with multiple sclerosis, providing new insights into the cause of the disease. The discovery is associated with a herpes virus and could lead to significant advancements in MS research and treatment.
Researchers analyzed data from BC MS Clinics' database and BC Perinatal Database Registry to compare pregnancy outcomes in women with MS to those without the disease. Babies born to mothers with MS did not have significantly different gestational age or birth weight, but mothers with greater disability had slightly elevated risk of adv...
A Rush University Medical Center scientist is studying cinnamon's effects on multiple sclerosis, a disease that attacks the central nervous system. The research aims to understand how cinnamon's anti-inflammatory property may counteract the disease process in mice.
Scientists at The University of Nottingham have discovered a synthetic chemical compound that reduces MS severity by inhibiting pro-inflammatory signals while stimulating interferon-beta production. The findings highlight a potential new mechanism for treating the chronic inflammatory disease, which affects over 100,000 people in the UK.